News

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trialTopline data…

2 years ago

Acerus Announces Resignation of CFO Effective November 20, 2022

TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert…

2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and…

2 years ago

Field Trip Health & Wellness Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 30, 2022, at 8:30 A.M. ET

TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”),…

2 years ago

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

Further Enhances Research Capabilities in Infectious Disease and BiodefenseDURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American:…

2 years ago

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company”…

2 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming…

2 years ago

Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,…

2 years ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer’s Disease

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as…

2 years ago

Tilray Medical Receives Verification From the Natural Health Science Foundation in Australia and New Zealand

Natural Health Science Foundation Assessment Further Verifies Tilray Medical’s High-Quality Standard and its CBD100 Product for Clinical Trial UseSYDNEY, Australia,…

2 years ago